Patents Assigned to Ontario Institute for Cancer Research
-
Publication number: 20240018600Abstract: There is described herein a method of prognosing and/or predicting disease progression and/or in subject with prostate cancer, the method comprising: a) providing a sample containing mitochondrial genetic material from prostate cancer cells; b) sequencing the mitochondrial genetic material with respect to at least 1 patient biomarker selected from CSB1, OHR, ATP8 and HV1 (hypervariable region 1); c) comparing the sequence of said patient biomarkers to control or reference biomarkers to determine mitochondrial single nucleotide variations (mtSNVs); and d) determining the a prostate cancer prognosis; wherein a relatively worse outcome is associated with the presence of mtSNVs in CSB1, OHR, ATP8 and a relatively better outcome is associated with the presence of mtSNVs in HV1.Type: ApplicationFiled: November 14, 2022Publication date: January 18, 2024Applicants: Ontario Institute for Cancer Research (OICR), UNIVERSITY HEALTH NETWORKInventors: Julia A. HOPKINS, Paul Boutros, Robert G. BRISTOW
-
Patent number: 11576981Abstract: The present application is directed to compounds of Formula (I)-(VIII): compositions comprising these compounds and their uses, for example as medicaments and/or diagnostics.Type: GrantFiled: December 6, 2018Date of Patent: February 14, 2023Assignee: ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR)Inventors: Rima Al-awar, Andrew Zhang, Ahmed Mamai
-
Patent number: 11566292Abstract: There is described herein a method of prognosing endocrine-only treatment in a subject with breast cancer, the method comprising: a) providing a tumor sample of the breast cancer; b) determining the expression level of at least 40 of the genes listed in Table 4 in the tumor sample; c) comparing said expression levels to a reference expression level of the group of genes from control samples from a cohort of subjects; and d) determining the residual risk associated with the breast cancer; wherein a statistically significant difference or similarity in the expression of the group of genes compared to the reference expression level corresponds to a residual risk associated with breast cancer.Type: GrantFiled: December 7, 2016Date of Patent: January 31, 2023Assignee: ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR)Inventors: Jane Bayani, John M. S. Bartlett, Cindy Q. Yao, Paul C. Boutros
-
Patent number: 11518764Abstract: The present application relates to compounds of Formula I or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.Type: GrantFiled: February 6, 2019Date of Patent: December 6, 2022Assignee: ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR)Inventors: Rima Al-awar, Methvin Isaac, Anh My Chau, Ahmed Mamai, Iain Watson, Gennady Poda, Pandiaraju Subramanian, Brian Wilson, David Uehling, Michael Prakesch, Babu Joseph, Justin-Alexander Morin
-
Patent number: 11505539Abstract: The present application relates to compounds of Formula I (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB and/or by degrading BCL6, such as cancer.Type: GrantFiled: December 21, 2018Date of Patent: November 22, 2022Assignee: Ontario Institute for Cancer Research (OICR)Inventors: Methvin Isaac, Anh My Chau, Ahmed Mamai
-
Patent number: 11499195Abstract: There is described herein a method of prognosing and/or predicting disease progression and/or in subject with prostate cancer, the method comprising: a) providing a sample containing mitochondrial genetic material from prostate cancer cells; b) sequencing the mitochondrial genetic material with respect to at least 1 patient biomarker selected from CSB1, OHR, ATP8 and HV1 (hypervariable region 1); c) comparing the sequence of the patient biomarkers to control or reference biomarkers to determine mitochondrial single nucleotide variations (mtSNVs); and d) determining the a prostate cancer prognosis; wherein a relatively worse outcome is associated with the presence of mtSNVs in CSB1, OHR, ATP8 and a relatively better outcome is associated with the presence of mtSNVs in HV1.Type: GrantFiled: June 2, 2017Date of Patent: November 15, 2022Assignees: Ontario Institute for Cancer Research, University Health NetworkInventors: Julia A. Hopkins, Paul Boutros, Robert G. Bristow
-
Patent number: 11364234Abstract: The present application relates to the treatment of nematode infections.Type: GrantFiled: September 10, 2019Date of Patent: June 21, 2022Assignees: The Governing Council of the University of Toronto, Ontario Institute for Cancer Research (OICR)Inventors: Peter Roy, Sean Harrington, Jacob Pyche, Daniel Kulke, Genna M. Luciani, Andrew Burns, Mark Lautens, Rachel Ross, David Uehling
-
Patent number: 11242351Abstract: The present application relates to compounds of Formula (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.Type: GrantFiled: December 21, 2018Date of Patent: February 8, 2022Assignee: ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR)Inventors: Rima Al-awar, Methvin Isaac, Anh My Chau, Ahmed Mamai, Iain Watson, Gennady Poda, Pandiaraju Subramanian, Brian Wilson, David Uehling
-
Patent number: 11214836Abstract: The invention features methods, devices, and kits for predicting the responsiveness of a cancer patient (e.g., a breast cancer patient, such as a grade 1, 2, or 3 breast cancer patient) to anthracycline treatment by determining the expression levels of four chromosomal instability (CIN) genes including HDGF, KIAA0286, RFC4, and MSH6, collectively referred to as CIN4. Patients that have a low CIN4 score benefit from anthracycline treatment compared patients with a high CIN4 score.Type: GrantFiled: July 15, 2015Date of Patent: January 4, 2022Assignee: Ontario Institute for Cancer ResearchInventors: Melanie Spears, John Bartlett, Fouad Yousif, Paul Boutros
-
Patent number: 11192880Abstract: The present application relates to compounds of Formula I or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB and/or by degrading BCL6, such as cancer.Type: GrantFiled: December 20, 2018Date of Patent: December 7, 2021Assignee: ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR)Inventors: Methvin Isaac, Anh My Chau
-
Patent number: 11015226Abstract: There is provided herein a method for determining a likelihood of resistance to anthracyclin, or poor survival, in a patient with cancer by identifying upregulation of at least one histone gene in the patient.Type: GrantFiled: October 4, 2016Date of Patent: May 25, 2021Assignee: ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR)Inventors: Melanie Spears, John M. Bartlett, Marsela Braunstein, Paul M. Krzyzanowski, Irina Kalatskaya, Lincoln Stein
-
Publication number: 20210106694Abstract: The present application is directed to compounds of Formula (I): compounds of Formula (II): compounds of Formula (III): and compounds of Formula (IV): compositions comprising these compounds and their uses, for example as medicaments and/or diagnostics. Specifically claimed are: (1) compounds containing reactive functional groups (compound of formula I), compounds containing compounds to be linked together (compound of formula II) and compounds having a reactive functional group/a compound to be linked (compound of formula IV), (2) an antibody-drug conjugate (compound of formula III), wherein the antibody is covalently attached by a linker to one or more drugs, (3) pharmaceutical compositions comprising compounds of Formula (II) or Formula (III), (4) treatment/diagnosis of disease comprising compounds of Formula (II) or Formula (III), and (5) methods of preparing an ADC of Formula III.Type: ApplicationFiled: December 20, 2018Publication date: April 15, 2021Applicant: Ontario Institute for Cancer Research (OICR)Inventors: Rima Al-awar, Ahmed Mamai
-
Publication number: 20210053978Abstract: The present application relates to compounds of Formula (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.Type: ApplicationFiled: December 21, 2018Publication date: February 25, 2021Applicant: Ontario Institute for Cancer Research (OICR)Inventors: Rima Al-awar, Methvin Isaac, Anh My Chau, Ahmed Mamai, Iain Watson, Gennady Poda, Pandiaraju Subramanian, Brian Wilson, David Uehling
-
Publication number: 20200397916Abstract: The present application is directed to compounds of Formula (I)-(VI): (I), (II), (III), (IV), (V) (VI), (VII) and (VIII), compositions comprising these compounds and their uses, for example as medicaments and/or diagnostics.Type: ApplicationFiled: December 6, 2018Publication date: December 24, 2020Applicant: Ontario Institute for Cancer Research (OICR)Inventors: Rima Al-Awar, Andrew Zhang, Ahmed Mamai
-
Publication number: 20200331921Abstract: The present application relates to compounds of Formula I (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.Type: ApplicationFiled: February 6, 2019Publication date: October 22, 2020Applicant: Ontario Institute for Cancer Research (OICR)Inventors: Rima Al-awar, Methvin Isaac, Anh My Chau, Ahmed Mamai, Lain Watson, Gennady Poda, Pandiaraju Subramanian, Brian Wilson, David Uehling, Michael Prakesch, Babu Joseph, Justin-Alexander Morin
-
Publication number: 20200325119Abstract: The present application relates to compounds of Formula I or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB and/or by degrading BCL6, such as cancer.Type: ApplicationFiled: December 20, 2018Publication date: October 15, 2020Applicant: Ontario Institute for Cancer Research (OICR)Inventors: Methvin Isaac, Anh My Chau
-
Publication number: 20200308147Abstract: The present application relates to compounds of Formula I (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB and/or by degrading BCL6, such as cancer.Type: ApplicationFiled: December 21, 2018Publication date: October 1, 2020Applicant: Ontario Institute for Cancer Research (OICR)Inventors: Methvin Isaac, Anh My Chau, Ahmed Mamai
-
Patent number: 10745760Abstract: There is provided herein, systems, devices and methods for determining a risk of recurrence of cancer following a cancer therapy of a patient by determining genomic instability of a tumour. There is further provided systems, devices and methods for categorizing a patient into a prognostic cancer sub-group by using copy number alterations.Type: GrantFiled: January 16, 2015Date of Patent: August 18, 2020Assignees: University Health Network, Ontario Institute for Cancer ResearchInventors: Paul Boutros, Robert G. Bristow, Emilie Lalonde
-
Patent number: 10557134Abstract: Described herein are approaches for the improved detection, identification, and/or quantification of target nucleic acids. These approaches provide a means of detecting, identifying, and/or quantifying rare target nucleic acid molecules, including DNA and RNA molecules, from the same sample, and in the same reaction, by using “hairpin barcode primers,” as the term is defined herein, to incorporate unique barcodes into target nucleic acids in a PCR pre-amplification step.Type: GrantFiled: February 24, 2016Date of Patent: February 11, 2020Assignees: TRUSTEES OF BOSTON UNIVERSITY, ONTARIO INSTITUTE FOR CANCER RESEARCHInventors: Tony Edward Godfrey, Anders Torbjoern Staahlberg, Paul Krzyzanowski
-
Publication number: 20180051277Abstract: Described herein are approaches for the improved detection, identification, and/or quantification of target nucleic acids. These approaches provide a means of detecting, identifying, and/or quantifying rare target nucleic acid molecules, including DNA and RNA molecules, from the same sample, and in the same reaction, by using “hairpin barcode primers,” as the term is defined herein, to incorporate unique barcodes into target nucleic acids in a PCR pre-amplification step.Type: ApplicationFiled: February 24, 2016Publication date: February 22, 2018Applicants: Trustees of Boston University, Ontario Institute for Cancer Research Mars CentreInventors: Tony Edward GODFREY, Anders Torbjoern STAAHLBERG, Paul KRZYZANOWSKI